Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients

被引：3

作者：

Trevisan, B. ^{[1
]}

Pepe, F. F. ^{[1
]}

Vallini, I. ^{[2
]}

Montagna, E. ^{[3
]}

Amoroso, D. ^{[4
]}

Berardi, R. ^{[5
]}

Butera, A. ^{[6
]}

Cagossi, K. ^{[7
]}

Cavanna, L. ^{[8
]}

Ciccarese, M. ^{[9
]}

Cinieri, S. ^{[10
]}

Cretella, E. ^{[11
]}

De Conciliis, E. ^{[12
]}

Febbraro, A. ^{[13
]}

Ferrau, F. ^{[14
]}

Ferzi, A. ^{[15
]}

Baldelli, A. ^{[16
]}

Fontana, A. ^{[17
]}

Gambaro, A. R. ^{[18
]}

Garrone, O. ^{[19
]}

Gebbia, V. ^{[20
]}

Generali, D. ^{[21
]}

Gianni, L. ^{[22
]}

Giovanardi, F. ^{[23
]}

Grassadonia, A. ^{[24
]}

Leonardi, V. ^{[25
]}

Sarti, S. ^{[26
]}

Musolino, A. ^{[27
]}

Nicolini, M. ^{[22
]}

Putzu, C. ^{[28
]}

Riccardi, F. ^{[29
]}

Santini, D. ^{[30
]}

Sarobba, M. G. ^{[31
]}

Schintu, M. G. ^{[32
]}

Scognamiglio, G. ^{[33
]}

Spadaro, P. ^{[34
]}

Taverniti, C. ^{[35
]}

Toniolo, D. ^{[36
]}

Tralongo, P. ^{[37
]}

Turletti, A. ^{[38
]}

Valenza, R. ^{[39
]}

Valerio, M. R. ^{[40
]}

Vici, P. ^{[41
]}

Clivio, L. ^{[42
]}

Torri, V. ^{[42
]}

Cazzaniga, M. E. ^{[1
]}

机构：

[1] Azienda Osped San Gerardo, Monza, Italy

[2] Osped Circolo & Fdn Macchi, Varese, Italy

[3] European Inst Oncol, Milan, Italy

[4] Osped Versilia, Camaiore, Italy

[5] Azienda Osped Univ Osped Riuniti, Torrette, Italy

[6] Nuovo Osped San Giovanni Dio, Florence, Italy

[7] Osped Ramazzini, Carpi, Italy

[8] Azienda Osped Piacenza, Piacenza, Italy

[9] Osped Vito Fazzi, Lecce, Italy

[10] Osped A Perrino, Brindisi, Italy

[11] Osped Bolzano, Bolzano, Italy

[12] ASL Asti, Asti, Italy

[13] Osped S Cuore Gesu Fatebenefratelli, Benevento, Italy

[14] Osped San Vincenzo, Taormina, Italy

[15] Azienda Osped Osped Civile Legnano, Magenta, Italy

[16] Osped San Salvatore, Coppito, Italy

[17] Azienda Osped Univ Pisana, Pisa, Italy

[18] ASST Fatebenefratelli Sacco, Milan, Italy

[19] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy

[20] Osped La Maddalena, Palermo, Italy

[21] Ist Ospitalieri Cremona, Cremona, Italy

[22] Osped Infermi, Rimini, Italy

[23] AUSL Romagna, Emilia Romagna, Italy

[24] Osped SS Annunziata, Taranto, Italy

[25] Osped Civ, Palermo, Italy

[26] IRCCS Ist Sci Romagnolo Studio Cura Tumori, Meldola, Italy

[27] Osped Parma, Parma, Italy

[28] Azienda Osped Univ, Sassari, Italy

[29] Osped Antonio Cardarelli, Naples, Italy

[30] Univ Campus Biomed, Rome, Italy

[31] Osped San Francesco, Nuoro, Italy

[32] Osped Giovanni Paolo II, Lecce, Italy

[33] Osped Valduce, Como, Italy

[34] Casa Cura Villa Salus Messina, Messina, Italy

[35] Osped Molinette, Turin, Italy

[36] Osped Circolo, Rho, Italy

[37] Osped Umberto I, Rome, Italy

[38] Osped Martini, Turin, Italy

[39] PO Vittorio Emanuele, Gela, Italy

[40] AOU Policlin Paolo Giaccone, Palermo, Italy

[41] INT Regina Elena, Rome, Italy

[42] IRCCS Mario Negri Inst Pharmacol Res, Milan, Italy

来源：

SCIENTIFIC REPORTS | 2023年 / 13卷 / 01期

关键词：

PHASE-II TRIAL; 1ST-LINE TREATMENT; INTERNATIONAL SOCIETY; ORAL VINORELBINE; CAPECITABINE; MANAGEMENT; RECOMMENDATIONS; ANGIOGENESIS; PACLITAXEL; WOMEN;

D O I：

10.1038/s41598-023-39386-x

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Nowadays, treatment of metastatic breast cancer (MBC) has been enriched with novel therapeutical strategies. Metronomic chemotherapy (mCHT) is a continuous and frequent administration of chemotherapy at a lower dose and so whit less toxicity. Thus, this strategy could be attractive for elderly MBC patients. Aim of this analysis is to provide insights into mCHT's activity in a real-life setting of elderly MBC patients. Data of patients & GE; 75 years old included in VICTOR-6 study were analyzed. VICTOR-6 is a multicentre, Italian, retrospective study, which collected data on mCHT in MBC patients treated between 2011 and 2016. A total of 112 patients were included. At the beginning of mCHT, median age was 81 years (75-98) and in 33% of the patients mCHT was the first line choice. Overall Response Rate (ORR) and Disease Control Rate (DCR) were 27.9% and 79.3%, respectively. Median PFS ranged between 7.6 and 9.1 months, OS between 14.1 and 18.5 months. The most relevant toxicity was the hematological one (24.1%); severe toxicity (grade 3-4) ranged from 0.9% for skin toxicity up to 8% for hematologic one. This is a large study about mCHT in elderly MBC patients, providing insights to be further investigated in this subgroup of frail patients.

引用

页数：9

共 50 条

[21] Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer-results of an exploratory case-control study
Krajnak, S.
Schnatz, C.
Almstedt, K.
Brenner, W.
Haertner, F.
Heimes, A-S
Lebrecht, A.
Makris, G-M
Schwab, R.
Hasenburg, A.
Schmidt, M.
Battista, M. J.
BREAST CANCER RESEARCH AND TREATMENT, 2020, 182 (02) : 389 - 399
[22] Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer:: final results of a multicenter phase II study
Schmid, P
Krocker, J
Morack, G
Heilmann, V
Blohmer, JU
Michniewicz, K
Köhler, G
Schaller-Kranz, T
Possinger, K
Elling, D
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2004, 130 (11) : 657 - 663
[23] Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer: final results of a multicenter phase II study
P. Schmid
J. Krocker
G. Morack
V. Heilmann
J.-U. Blohmer
K. Michniewicz
G. Köhler
T. Schaller-Kranz
K. Possinger
D. Elling
Journal of Cancer Research and Clinical Oncology, 2004, 130 : 657 - 663
[24] Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: Final results of the DOGMES multicentre GINECO trial
Falandry, C.
Brain, E.
Bonnefoy, M.
Mefti, F.
Jovenin, N.
Rigal, O.
Guillem, O.
El Kouri, C.
Uwer, L.
Abadie-Lacourtoisie, S.
Cretin, J.
Jacquin, J. P.
Paraiso, D.
Freyer, G.
EUROPEAN JOURNAL OF CANCER, 2013, 49 (13) : 2806 - 2814
[25] Use of Eribulin mesylate as second-line therapy in elderly patients with HER/2 negative metastatic breast cancer (MBC): efficacy, tolerability and Quality of Life
De Luca, R.
Alu, M.
Genova, G.
Grassadonia, A.
Cicero, G.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (24) : 12727 - 12734
[26] Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study
O'Shaughnessy, Joyce
Brezden-Masley, Christine
Cazzaniga, Marina
Dalvi, Tapashi
Walker, Graham
Bennett, James
Ohsumi, Shozo
BREAST CANCER RESEARCH, 2020, 22 (01)
[27] In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium
Lobbezoo, D. J. A.
van Kampen, R. J. W.
Voogd, A. C.
Dercksen, M. W.
van den Berkmortel, F.
Smilde, T. J.
van de Wouw, A. J.
Peters, F. P. J.
van Riel, J. M. G. H.
Peters, N. A. J. B.
de Boer, M.
Peer, P. G. M.
Tjan-Heijnen, V. C. G.
ANNALS OF ONCOLOGY, 2016, 27 (02) : 256 - 262
[28] Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE
Leo, Silvana
Arnoldi, Ermenegildo
Repetto, Lazzaro
Coccorullo, Zaira
Cinieri, Saverio
Fedele, Palma
Cazzaniga, Marina
Lorusso, Vito
Latorre, Agnese
Campanella, Giovanna
Ciccarese, Mariangela
Accettura, Caterina
Pisconti, Salvatore
Rinaldi, Antonio
Brunetti, Cosimo
Raffaele, Mimma
Coltelli, Luigi
Spazzapan, Salvatore
Fratino, Lucia
Petrucelli, Luciana
Biganzoli, Laura
ONCOLOGIST, 2019, 24 (06) : E232 - E240
[29] Quality of life in metastatic breast cancer patients under chemotherapy or supportive care: a single-institution comparative study
Karamouzis, M. V.
Ioannidis, G.
Rigatos, G.
EUROPEAN JOURNAL OF CANCER CARE, 2007, 16 (05) : 433 - 438
[30] Bevacizumab and First-line Chemotherapy for Older Patients with Advanced Colorectal Cancer: Final Results of a Community-based Observational Italian Study
Lutrino, Stefania Eufemia
Bergamo, Francesca
Schirripa, Marta
Rosati, Gerardo
Avallone, Antonio
Giampieri, Riccardo
Cordio, Stefano
Berretta, Massimiliano
Llimpe, Fabiola Rojas
Pisa, Federica Edith
Lonardi, Sara
Loupakis, Fotios
Fasola, Gianpiero
Aprile, Giuseppe
ANTICANCER RESEARCH, 2015, 35 (04) : 2391 - 2399

← 1 2 3 4 5 →